Pre-Use Susceptibility to Ceftaroline in Clinical Staphylococcus aureus Isolates from Germany: Is There a Non-Susceptible Pool to be Selected?
Open Access
- 8 May 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0125864
Abstract
Ceftaroline is a new cephalosporin active against Methicillin-resistant Staphylococcus aureus (MRSA). Based on a representative collection of clinical S. aureus isolates from Germany, supplemented with isolates of clonal lineages ST228 and ST239, we demonstrate the in-vitro susceptibility towards ceftaroline prior to its introduction into clinical use for a total of 219 isolates. Susceptibility testing was performed by broth microdilution, disc diffusion and Etest, respectively. Results were interpreted according to EUCAST guidelines and showed considerable variance in dependence on clonal affiliation of the isolates tested. Among isolates of widespread hospital-associated lineages we found a high proportion of clinical isolates with MICs close to the EUCAST breakpoint (MIC50/90 1.0/1.5 mg/L); currently, interpretation of these “borderline” MICs is complicated by a lack of concordant susceptibility testing methods and reasonable breakpoint determination. Isolates of clonal lineages ST228 and ST239 demonstrated increased MIC50/90 values of 2.5/3.33 mg/L. Sequencing of mecA revealed no association of resistance to a specific mecA polymorphism, but rather reveals two regions in the non-penicillin-binding domain of PbP2a which displayed different combinations of mutations putatively involved in resistance development. This study provides national baseline data to (i) adjust susceptibility testing methods and current breakpoints to clinical and epidemiological requirements, (ii) evaluate current breakpoints with respect to therapeutic outcome and (iii) monitor further resistance evolution.Keywords
This publication has 32 references indexed in Scilit:
- Population Dynamics among Methicillin-Resistant Staphylococcus aureus Isolates in Germany during a 6-Year PeriodJournal of Clinical Microbiology, 2012
- Properties of a Novel PBP2A Protein Homolog from Staphylococcus aureus Strain LGA251 and Its Contribution to the β-Lactam-resistant PhenotypeJournal of Biological Chemistry, 2012
- Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009Antimicrobial Agents and Chemotherapy, 2011
- Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive studyThe Lancet Infectious Diseases, 2011
- Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, SpainBMC Microbiology, 2010
- Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in ItalyAnnals of Clinical Microbiology and Antimicrobials, 2009
- Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east AsiaThe Lancet Infectious Diseases, 2009
- In Vitro Selection and Characterization of Ceftobiprole-Resistant Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- spa Typing of Staphylococcus aureus as a Frontline Tool in Epidemiological TypingJournal of Clinical Microbiology, 2008
- Replacement of methicillin-resistant Staphylococcus aureus clones in Hungary over time: a 10-year surveillance studyClinical Microbiology and Infection, 2007